A Rare Case of Primary Anorectal Melanoma and a Review of the Current Landscape of Therapy

被引:9
作者
Yeung, Ho-Man [1 ]
Gupta, Brinda [1 ]
Kamat, Bhishak [2 ]
机构
[1] Temple Univ Hosp & Med Sch, Dept Med, Philadelphia, PA 19140 USA
[2] Temple Univ Hosp & Med Sch, Dept Radiol, Philadelphia, PA 19140 USA
来源
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES | 2020年 / 10卷 / 04期
关键词
Anorectal melanoma; muscosal melanoma; immunotherapy; gastrointestinal cancer; ABDOMINOPERINEAL RESECTION; MUCOSAL MELANOMA; LOCAL EXCISION; IPILIMUMAB; EFFICACY; KIT; FEATURES; SAFETY; TRIAL;
D O I
10.1080/20009666.2020.1787809
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Anorectal mucosal melanoma (ARMM) is an uncommon and highly aggressive malignancy. Given its rarity, there is insufficient evidence on the optimal medical management which presents as a clinical challenge to its diagnosis and treatment. Treatment of ARMM typically involves a multimodal approach including surgical resection, chemotherapy, targeted therapy and/or immunotherapy. Case Presentation: Here, we present a case of a 78-year-old female who presented with a four-month history of rectal bleeding and bowel incontinence. Ultimately, colonoscopy revealed a mass at the anal verge, and biopsy of the mass showed malignant cells that stained positive for S100, Melan-A and HMB-45, consistent with the diagnosis of malignant melanoma. Molecular testing revealed noBRAF, KITorNRASgene mutations. PD-L1 immunohistochemistry showed tumor proportion score of 1%. She underwent abdominoperineal resection with a plan to initiate immunotherapy with an anti-PD-1 checkpoint inhibitor. This case highlights a rare aggressive malignancy and reviews its treatment option, which are mostly extrapolated from its cutaneous counterpart and some derived from a few case reports. Due to its rarity, there is no consensus guideline for the treatment of ARMM.
引用
收藏
页码:371 / 376
页数:6
相关论文
共 32 条
  • [11] A Phase 2 Trial of Dasatinib in Patients With Locally Advanced or Stage IV Mucosal, Acral, or Vulvovaginal Melanoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2607)
    Kalinsky, Kevin
    Lee, Sandra
    Rubin, Krista M.
    Lawrence, Donald P.
    Iafrarte, Anthony J.
    Borger, Darell R.
    Margolin, Kim A.
    Leitao, Mario M., Jr.
    Tarhini, Ahmad A.
    Koon, Henry B.
    Pecora, Andrew L.
    Jaslowski, Anthony J.
    Cohen, Gary I.
    Kuzel, Timothy M.
    Lao, Christopher D.
    Kirkwood, John M.
    [J]. CANCER, 2017, 123 (14) : 2688 - 2697
  • [12] Primary Anorectal Melanoma
    Khan, Maliha
    Bucher, Nora
    Elhassan, Ahmed
    Barbaryan, Aram
    Ali, Alaa M.
    Hussain, Nasir
    Mirrakhimov, Aibek E.
    [J]. CASE REPORTS IN ONCOLOGY, 2014, 7 (01): : 164 - 170
  • [13] Biochemotherapy in patients with metastatic anorectal mucosal melanoma
    Kim, KB
    Sanguino, AM
    Hodges, C
    Papadopoulos, NE
    Eton, O
    Camacho, LH
    Broemeling, LD
    Johnson, MM
    Ballo, MT
    Ross, MI
    Gershenwald, JE
    Lee, JE
    Mansfield, PF
    Prieto, VG
    Bedikian, AY
    [J]. CANCER, 2004, 100 (07) : 1478 - 1483
  • [14] Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
    Lian, Bin
    Si, Lu
    Cui, Chuanliang
    Chi, Zhihong
    Sheng, Xinan
    Mao, Lili
    Li, Siming
    Kong, Yan
    Tang, Bixia
    Guo, Jun
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4488 - 4498
  • [15] Malaguarnera G., 2018, ONCOTARGET, V9, P8785, DOI DOI 10.18632/ONCOTARGET.23835
  • [16] Abdominoperineal Resection Provides Better Local Control But Equivalent Overall Survival to Local Excision of Anorectal Malignant Melanoma A Systematic Review
    Matsuda, Akihisa
    Miyashita, Masao
    Matsumoto, Satoshi
    Takahashi, Goro
    Matsutani, Takeshi
    Yamada, Takeshi
    Kishi, Taro
    Uchida, Eiji
    [J]. ANNALS OF SURGERY, 2015, 261 (04) : 670 - 677
  • [17] What are melanocytes really doing all day long...?
    Plonka, P. M.
    Passeron, T.
    Brenner, M.
    Tobin, D. J.
    Shibahara, S.
    Thomas, A.
    Slominski, A.
    Kadekaro, A. L.
    Hershkovitz, D.
    Peters, E.
    Nordlund, J. J.
    Abdel-Malek, Z.
    Takeda, K.
    Paus, R.
    Ortonne, J. P.
    Hearing, V. J.
    Schallreuter, K. U.
    [J]. EXPERIMENTAL DERMATOLOGY, 2009, 18 (09) : 799 - 819
  • [18] BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival
    Ponti, Giovanni
    Manfredini, Marco
    Greco, Stefano
    Pellacani, Giovanni
    Depenni, Roberta
    Tomasi, Aldo
    Maccaferri, Monia
    Cascinu, Stefano
    [J]. ANTICANCER RESEARCH, 2017, 37 (12) : 7043 - 7048
  • [19] Ipilimumab for Patients With Advanced Mucosal Melanoma
    Postow, Michael A.
    Luke, Jason J.
    Bluth, Mark J.
    Ramaiya, Nikhil
    Panageas, Katherine S.
    Lawrence, Donald P.
    Ibrahim, Nageatte
    Flaherty, Keith T.
    Sullivan, Ryan J.
    Ott, Patrick A.
    Callahan, Margaret K.
    Harding, James J.
    D'Angelo, Sandra P.
    Dickson, Mark A.
    Schwartz, Gary K.
    Chapman, Paul B.
    Gnjatic, Sacha
    Wolchok, Jedd D.
    Hodi, F. Stephen
    Carvajal, Richard D.
    [J]. ONCOLOGIST, 2013, 18 (06) : 726 - 732
  • [20] Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib
    Quintas-Cardama, Alfonso
    Lazar, Alexander J.
    Woodman, Scott E.
    Kim, Kevin
    Ross, Merrick
    Hwu, Patrick
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12): : 737 - 740